← Back to Search

Virus Therapy

CDK-002 for Solid Tumors

Phase 1 & 2

Waitlist Available

Led By Roger Cohen, MD

Research Sponsored by Codiak BioSciences

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 2 years

Awards & highlights

Study Summary

This trial is testing a new drug, CDK-002, to see if it is safe and effective in treating subjects with advanced/metastatic, recurrent, injectable solid tumors, specifically head and neck squamous cell cancer (HNSCC), triple negative breast cancer (TNBC), anaplastic thyroid carcinoma (ATC), and cutaneous squamous cell carcinoma (cSCC). CDK-002 will be administered intratumorally (IT).

Eligible Conditions

Solid Tumors

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

To determine the safety and tolerability of ascending doses of CDK-002

Trial Design

1Treatment groups

Experimental Treatment

Group I: CDK-002Experimental Treatment1 Intervention

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

CDK-002

2020

Completed Phase 2

~30

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Codiak BioSciencesLead Sponsor

2 Previous Clinical Trials

11 Total Patients Enrolled

Roger Cohen, MDPrincipal InvestigatorUniversity of Pennsylvania Hospital

4 Previous Clinical Trials

233 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are volunteers still being recruited for this research?

"This particular clinical trial, as indicated on clinicaltrials.gov, is not enrolling patients currently. Although, it's worth noting that the study was last updated on September 27th, 2020 and there are 2584 other trials actively recruiting patients."

Answered by AI

At how many different hospitals is this research project being conducted?

"Currently, there are 4 clinical trial sites enrolling patients for this study. To help participants minimize travel requirements, 2 of the locations are in Scottsdale and Philadelphia, with the other 2 located in New york."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors

2020. "A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04592484.